NEW YORK - Goldman Sachs & Co (NYSE:GS). LLC has disclosed its recent dealings in the shares of Mural Oncology PLC, a company specializing in cancer treatment research and development. According to a statement released on May 15, 2025, the financial institution engaged in transactions involving Mural Oncology’s USD 0.01 ordinary shares on Wednesday, May 14.
The disclosure, mandated under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2013, reveals that Goldman Sachs holds both long and short positions in Mural Oncology. The long position consists of 90,974 shares, representing approximately 0.52% of the company’s issued share capital, while the short position accounts for 183,665 shares, or about 1.06%.
Additionally, Goldman Sachs reported having derivatives in the form of swaps, with 89,372 shares at a 0.51% stake. The transactions included small purchases of shares at a price of $2.58 per unit.
The dealings come at a time when Mural Oncology is under increased scrutiny from investors, given the volatile nature of biotech stocks and the high stakes involved in the development of new cancer treatments. The disclosure did not indicate any agreements, arrangements, or understandings related to the voting rights of the relevant securities, nor any future acquisition or disposal of the securities.
Goldman Sachs provided contact details for further inquiries, listing Papa Lette and Andrzej Szyszka as representatives, along with their respective contact numbers. The information, sourced from a press release statement, is part of routine disclosures by entities holding significant positions in publicly traded companies, ensuring transparency in financial markets.
Investors and market observers often monitor such disclosures to gauge the sentiment and strategies of major financial institutions regarding their investments in various companies. Mural Oncology’s share performance and the interest of financial institutions like Goldman Sachs can influence market perceptions and investment decisions in the biotech sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.